News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me
December, 2024
December 2024
M T W T F S S
 1
2345678
9101112131415
16171819202122
23242526272829
3031  
Daniel Gerlach: Pan-KRAS inhibitors displaying potent anti-tumor activity in tumors with KRAS allele amplification
Daniel Gerlach/X
Dec 25, 2024, 15:54

Daniel Gerlach: Pan-KRAS inhibitors displaying potent anti-tumor activity in tumors with KRAS allele amplification

Daniel Gerlach, Associate Scientific Director, Computational Biology Oncology at Boehringer Ingelheim, posted on X about recent paper by him as co-author, titled “Pan-KRAS inhibitors BI-2493 and BI-2865 display potent anti-tumor activity in tumors with KRAS wild-type allele amplification” published on AACR Journals.

Authors: Antonio Tedeschi, Fiorella Schischlik, Francesca Rocchetti, Johannes Popow, Florian Ebner, Daniel Gerlach, Antonia Geyer, Valeria Santoro, Andrew S. Boghossian, Matthew G. Rees, Melissa M. Ronan, Jennifer A. Roth, Jesse Lipp, Matthias Samwer, Michael Gmachl, Norbert Kraut, Mark Pearson, Dorothea Rudolph

Daniel Gerlach: Pan-KRAS inhibitors displaying potent anti-tumor activity in tumors with KRAS allele amplification

“Excited to share our recent work on the pan-KRAS inhibitors BI-2493 and BI-2865, displaying potent anti-tumor activity in tumors with KRAS wild-type allele amplification.

Great team effort by Boehringer Ingelheim.”

AACR Journals Andrew S. Boghossian Antonia Geyer Antonio Tedeschi BI-2493 BI-2865 Boehringer Ingelheim cancer Daniel Gerlach Dorothea Rudolph Fiorella Schischlik Florian Ebner Francesca Rocchetti Jennifer A. Roth Jesse Lipp Johannes Popow Mark Pearson Matthew G. Rees Matthias Samwer Melissa M. Ronan Michael Gmachl Norbert Kraut OncoDaily Oncology Pan-KRAS inhibitors Valeria Santoro
Special Coverage
Science
Dec 25, 2024, 15:54
Daniel Gerlach: Pan-KRAS inhibitors displaying potent anti-tumor activity in tumors with KRAS allele amplification
Science
Dec 25, 2024, 15:49
Melvin LK Chua: The mutational landscape of Radioresistant Cancers
Blog
Dec 25, 2024, 15:30
DCCPS Digest, December 2024 - NCI Division of Cancer Control and Population Sciences
Blog
Dec 25, 2024, 15:28
Joy (Herd) Lawn: The Lancet Commission on Evidence-Based Implementation in Global Health
Science
Dec 25, 2024, 15:16
Treatment Selection for the High-risk Patient with Stage I NSCLC
Blog
Dec 25, 2024, 15:14
Why World Cancer Day? - Union for International Cancer Control
Blog
Dec 25, 2024, 15:09
Stephanie Saw: First line and post-progression treatment options for advanced EGFR-mutated NSCLC
Science
Dec 25, 2024, 14:58
Myeloma Paper of the Day, December 25th, suggested by Robert Orlowski
Science
Dec 25, 2024, 14:49
Akhil Santhosh: Fruquitinib with or without paclitaxel in pretreated advanced gastric cancer
Radiotherapy
Dec 25, 2024, 14:47
What Is Proton Beam Therapy and How It Works? Pros and Cons
Science
Dec 25, 2024, 14:47
Andrea Necchi: Neoadjuvant Chemotherapy VI-RADS Scores for Assessing Bladder Cancer Response to Neoadjuvant Immunotherapy with Multiparametric MRI
Science
Dec 25, 2024, 14:44
Hung Trinh's review on breakthrough of solid tumor treatment: CAR-NK immunotherapy